Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors

NCT04306900 is registered in ClinicalTrials.gov with Trishula Therapeutics, Inc. as lead sponsor.

NCT NCT04306900
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04306900 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors
Lead sponsor
Trishula Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
March 30, 2020
Completion date
March 27, 2024
Enrollment
185 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult